🇺🇸 FDA
Patent

US 8883448

Mutated ras peptides for generation of CD8+ cytotoxic T lymphocytes

granted A61KA61K39/00A61K40/11

Quick answer

US patent 8883448 (Mutated ras peptides for generation of CD8+ cytotoxic T lymphocytes) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K39/00, A61K40/11, A61K40/4253, A61P